Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2023 Jul 1;108(7):1715-1717.
doi: 10.3324/haematol.2022.282440.

Venetoclax response prediction in acute myeloid leukemia: are we Finnish-ed with uncertainty?

Brett Stevens  1 , Daniel A Pollyea  2
Affiliations
Editorial

Venetoclax response prediction in acute myeloid leukemia: are we Finnish-ed with uncertainty?

Brett Stevens et al. Haematologica. .
No abstract available

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
The current and hopeful future of treatment decision-making involving venetoclax in patients with acute myeloid leukemia. (A) Currently, venetoclax-based regimens are prescribed with no insight into the likelihood that the regimen will be effective, akin to a spin of the roulette wheel. (B) In the future, practitioners may have access to rapid and reliable ex vivo testing that can help them to recommend a conventional venetoclax-based therapy, a venetoclax "triple combination", or a non-venetoclax-containing regimen.
See this image and copyright information in PMC

Comment on

  • Ex vivo venetoclax sensitivity testing predicts treatment response in acute myeloid leukemia.
    Kuusanmäki H, Kytölä S, Vänttinen I, Ruokoranta T, Ranta A, Huuhtanen J, Suvela M, Parsons A, Holopainen A, Partanen A, Kuusisto MEL, Koskela S, Räty R, Itälä-Remes M, Västrik I, Dufva O, Siitonen S, Porkka K, Wennerberg K, Heckman CA, Ettala P, Pyörälä M, Rimpiläinen J, Siitonen T, Kontro M. Kuusanmäki H, et al. Haematologica. 2023 Jul 1;108(7):1768-1781. doi: 10.3324/haematol.2022.281692. Haematologica. 2023. PMID: 36519325 Free PMC article.

References

    1. DiNardo CD, Jonas BA, Pullarkat V, et al. . Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N Engl J Med. 2020;383(7):617-629. - PubMed
    1. Wei AH, Montesinos P, Ivanov V, et al. . Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial. Blood. 2020;135(24):2137-2145. - PMC - PubMed
    1. Pollyea DA, Pratz KW, Wei AH, et al. . Outcomes in patients with poor-risk cytogenetics with or without TP53 mutations treated with venetoclax and azacitidine. Clin Cancer Res. 2022;28(24):5272-5279. - PMC - PubMed
    1. Pollyea DA, DiNardo CD, Arellano ML, et al. . Impact of venetoclax and azacitidine in treatment-naive patients with acute myeloid leukemia and IDH1/2 mutations. Clin Cancer Res. 2022;28(13):2753-2761. - PMC - PubMed
    1. Kuusanmaki H, Kytola S, Vanttinen I, et al. . Ex vivo venetoclax sensitivity testing predicts treatment response in acute myeloid leukemia. Haematologica. 2023;108(7):1768-1781. - PMC - PubMed

MeSH terms

Substances